Skip to main content
PGIM LogoPGIM Logo
    • Megatrends
    • Annual Best Ideas
    • OutFront Series
    • Quarterly Market Outlooks
    • Vantage Point Series
    • Market Events
    • Thought Leadership
    • Events & Webinars
    • Video Library
    • Podcasts
    • Investing in Alternatives
    • Risk Management
    • ESG Investing
    • Opportunities in EM
  • Alternatives

    • PGIM Private Alternatives
    • PGIM Private Capital
    • PGIM Real Estate
    • Montana Capital Partners (PE)

    Equity & Fixed Income

    • PGIM Fixed Income
    • Jennison Associates

    Solutions

    • PGIM DC Solutions
    • PGIM Multi-Asset Solutions
    • PGIM Quantitative Solutions

    Intermediary Distribution

    • PGIM Investments
    • Clients We Serve
    • Defined Contribution
    • Financial Advisors
    • Institutional Relationships
    • Global Locations
    • Contact Us
    • Overview
    • Leadership
    • History
    • Our Businesses
    • Diversity, Equity & Inclusion
    • Global Locations
    • Contact Us
    • Subscribe
    • Request for Information
    • Careers at PGIM
    • Job Opportunities
    • All News
    • Press Releases
    • In the News
    • Facts & Figures
    • Media Contacts
Double helix of DNA inside bubble on navy background
Outfront

The Healthcare Revolution

The Healthcare Revolution

A Prescription For Growth

  • Download PDF

Introduction

It’s a defining moment for healthcare. From drug discovery to digital delivery, a once-in-a-generation revolution is promising to introduce new cures for some of the most intractable illnesses, as well as personalized treatment at a lower cost.

Innovation is flourishing (see chart). Total pharmaceutical, MedTech and biotech patent applications increased from more than 197,800 globally in 2011 to almost 357,640 in 2021. For every drug or new medical device that’s approved, many patents are filed to protect intellectual property. 

Innovation is flourishing

New drugs have the potential to transform treatment of serious diseases, including diabetes, obesity, cardiovascular disease and cancer. Yet not all healthcare companies will be winners. While the true innovators will prosper, others look likely to be left behind.

 

Source: World Intellectual Property Indicators, 2023

 

MedTech, biotech & pharmaceutical patent applications
358,000
filed globally in a single year

CHAPTER 1

DAWN OF A NEW ERA IN DRUG DISCOVERY AND TREATMENT

GLP-1 BLOCKBUSTER DRUGS SET TO BE “WORLD’S LARGEST PHARMACEUTICAL”

Our belief is that over the next three to five years, GLP as a class will become the largest pharmaceutical the world has ever seen. Demand is being driven and will continue to be driven by Type 2 diabetics and by people looking to lose weight.
Daniel MatviyenkoPortfolio Manager, Healthcare StrategiesJennison Associates

As a leader in developing GLP-1 drugs, Novo Nordisk has swiftly become Europe’s most valuable quoted company.

As of March 26, its market capitalization was approximately $576.5 billion, propelled by the prospects for the Wegovy and Ozempic anti-obesity drugs. On August 8, 2023, Novo Nordisk announced that its medication also reduced the risk of heart attacks or strokes, spurring the latest leap in its share price.

Source: Drug Discovery & Development, 2024

Eli Lilly, the U.S. pharmaceutical giant with the Mounjaro anti-obesity drug, has seen a still greater stock surge.

Its share price was up almost 130% over the past 12 months, as of March 26, giving Eli Lilly a market capitalization of $734.6 billion.

Source: Drug Discovery & Development, 2024

With obesity at the root of many health problems, demand from the huge U.S. market alone is outstripping supply. 

Indeed, brokers estimate the weight-loss drugs market could grow from $6 billion to as much as $100 billion by the end of the decade.

The popularity of the weight loss drugs could also create new consumers of lifestyle purchases as a healthier population looks to stay in shape.

Source: Reuters, 2023

As the weight comes off, lifestyles will change. As people become more active, they will start investing in new hobbies, which could drive more purchases of consumer products. People with obesity spend $2,000 more a year on medical costs, so the savings could be added back to a household budget.
Scott SwansonPrincipalPGIM Fixed Income

But Novo Nordisk and Eli Lilly will soon see competition. 

While their specific drugs are protected by patents, the GLP-1 class of medications originally developed for Type 2 diabetes is not. More than 70 anti-obesity treatments are in development, according to STAT, a medical news site.

Source: MIT Technology Review, 2024

 

GENE EDITING TO HELP MILLIONS

Gene therapy is a game changer that’s arisen from decades of scientific research and could help millions of people.

In development since the 1990s, it promises to transform treatment of serious diseases such as cancer, as well as neurological, blood, immunological and cardiovascular illnesses. It’s one of the fastest-growing areas of healthcare, with over 2,000 therapies in development globally. 

Source: Scientific American, 2021

Source: BBC, 2023

Healthcare can also be tailored to a person’s genetics. 

For instance, clinical trials are currently testing mRNA vaccines against a range of cancer types including melanoma, ovarian, head and neck, colorectal, lung and pancreatic. These are the first cancer therapies entirely tailored to one patient’s DNA.

$25.84 BN

The global gene therapy market is expected to increase from $6.93 billion in 2023 to $25.84 billion by 2028. 

That’s a remarkable compound annual growth rate exceeding 30%.

 

Source: Market Data Forecast. Gene Therapy Market. March 2023

And yet these therapies come with a high price tag, which are an obstacle to their use. 

For instance, treatments for beta-thalassemia and hemophilia, two blood disorders, cost $2.8 million and $3.5 million respectively.

Source: Scientific American, 2022; Reuters, 2022

AI ACCELERATES DRUG DISCOVERY

As well as transforming areas of healthcare such as diagnostics, AI promises to shave years off the time taken to develop a drug.

This will speed time to market as well as cutting the substantial costs and risks of drug development.

For instance, AMGEN, the pharmaceutical giant, is leveraging a data-driven machine learning model, ATOMIC, to speed up clinical trials.

By 2030, it says, it expects AI to help shave two years off the decade or more it typically takes to develop a drug.

Source: Reuters, 2023

The U.S. Food & Drug Administration received about 300 applications incorporating AI or machine learning in drug development from 2016 through 2022.

Over 90% of those applications came in the last two years and most were for use of AI at some point in the clinical development stage.

Source: Reuters, 2023

CHAPTER 2

NEW FRONTIERS IN THE DELIVERY OF HEALTHCARE

TAILORING TREATMENT TO GENES

Gene sequencing has opened the door to medicine that’s tailored to an individual’s genetic make-up.

In 2003, the Human Genome Project finished mapping the 20,000 genes in humans, paving the way for understanding of which genes are linked to hereditary diseases. This has led to the development of new diagnostic methods and treatments.

Individuals can take a more proactive approach to their health.

For as little as $100 to $2,000 it’s possible to buy a genetic test showing people what illnesses such as diabetes or cancer they’re at high risk from. Such a personalized health profile paves the way for preventative medicine, alerting people to take treatments or change their lifestyles.

WEARABLES AND REAL-TIME BIOMETRICS

Wearable devices can operate in tandem with genetic testing, going way beyond the original fitness trackers. 

Smartwatches, bracelets and rings track heart rates, blood sugar, exercise levels and sleep patterns – but they have also evolved to diagnose diseases such as cancer and heart disease, as well as to track real-time biometrics including blood pressure.

 

The market for wearable devices and related apps is growing swiftly.

It is forecast to rise to a total of 440 million in 2024, according to Deloitte.

 

ROBOTICS

Robot surgeons are no longer a thing of the future. 

More than 11 million robotic surgeries have been performed worldwide using “da Vinci” robots. The surgeon guides the robot through a console, making it possible to operate through small incisions. 

According to research from Bain & Company, the market is already worth more than $3 billion worldwide and will continue to grow, with applications across a range of areas. 

Sources: Medicina, "New Robotic Platforms in General Surgery: What’s the Current Clinical Scenario?" 2023, Bain & Company, 2023

 

10-Year Growth Projection by Specialty Type

Source: Bain & Company, 2023

Source: Medi-Tech Insights, 2022

Increasingly, robots are also being used to replace care workers in countries such as Japan and China, where people are aging fast. 

They assist the elderly with walking, standing, rehabilitation and bathing.

CHAPTER 3

THE CONUNDRUM: HOW TO PICK WINNERS AND AVOID LOSERS

High M&A in face of patent cliff shows potential for both winners and losers.

While Novo Nordisk and Eli Lilly have risen to become two of the most valuable companies globally in recent years, other healthcare companies have struggled. Broadly speaking, the sector has trailed global equity markets. During 2023, for instance, the MSCI World Health Care Index rose by just 4.27% compared with the MSCI World’s 24.42% rise. 

 

Cumulative Index Performance

Source: MSCI, 2024

The broad index performance masks a wide range of returns. 

The share prices of pharmaceutical firms that do not have drug pipelines benefiting from next-generation drugs are languishing. There’s a patent cliff looming: the percentage of prescription drug sales at patent risk in 2027-2028 will reach the highest level since 2015, Evaluate Pharma says.

Sources: Scientific American, 2022 | Reuters, 2022, Evaluate Pharma, 2023

To replenish drug pipelines, pharmaceutical companies have been acquiring smaller companies with promising drugs in development.

The number of acquisitions rose to 135 in 2023, up from 126 in 2022, according to Evaluate. The value of these acquisitions reached $153 billion for 2023, the highest since 2019’s $239 billion.

Sources: Scientific American, 2022 | Reuters, 2022, Evaluate Pharma, 2023

Five Largest Acquisitions in 2023 Q4

Source: Fierce Pharma, 2024

THE LONG AND THE SHORT OF IT

All in all, healthcare’s wave of innovation and growth bodes well for investment opportunities. But investors will need to be highly selective.

An experienced manager can really look and take advantage of the volatility on both the long and the short side, creating a hedged portfolio that is defensive, by using knowledge and expertise seeking to find the winners and losers in volatile sectors.
Debra NetschertPortfolio ManagerJennison Associates

CONCLUSION

The healthcare industry is pushing at new frontiers that should lead to profits growth. 

In pharmaceuticals alone, revenues are estimated to climb from $1.1 trillion in 2023 to $1.6 trillion in 2028, according to Evaluate’s forecasts. The growth rate may be still greater in biotech and MedTech.

To give a sense of the scale of innovation, 2021’s 357,640 MedTech, biotech and pharmaceutical patent applications globally compare with 379,000 for computer technology. Clearly, today’s healthcare industry is a hotbed of innovation.

Yet there will be a big gap in the fortunes of winners and losers.

We want to own the stocks of those companies where it's true innovation. Where as we look out three years, this company has created a market or changed an existing market by improving the outcomes for the patients while at the same time improving the cost profile of that therapy.
Daniel MatviyenkoPortfolio Manager, Healthcare StrategiesJennison Associates

You may also like

S.4 Ep.3: Healthy Returns - Identifying Future Winners Amid Rapid Medical Innovation

S.4 Ep.3: Healthy Returns - Identifying Future Winners Amid Rapid Medical Innovation

Mar 20, 2024

With new breakthroughs emerging in healthcare, identifying future winners will lead investors to new opportunities.

Catching the Great AI Wave
Equity

Catching the Great AI Wave

Oct 16, 2023

Learn why we believe AI heralds a technological transformation, one that will be as deep and long lasting as the advent of the internet and mobile computing.

Healthcare Opportunities in 2023 and Beyond
Equity

Healthcare Opportunities in 2023 and Beyond

May 23, 2023

The pace of healthcare innovation could position the sector to be the next decade’s secular leader.

These materials represent the views, opinions and recommendations of the author(s) regarding the economic conditions, asset classes, securities, issuers or financial instruments referenced herein. Distribution of this information to any person other than the person to whom it was originally delivered and to such person’s advisers is unauthorized, and any reproduction of these materials, in whole or in part, or the divulgence of any of the contents hereof, without prior consent of PGIM is prohibited. Certain information contained herein has been obtained from sources that PGIM believes to be reliable as of the date presented; however, PGIM cannot guarantee the accuracy of such information, assure its completeness, or warrant such information will not be changed. The information contained herein is current as of the date of issuance (or such earlier date as referenced herein) and is subject to change without notice. PGIM has no obligation to update any or all of such information; nor do we make any express or implied warranties or representations as to the completeness or accuracy or accept responsibility for errors. These materials are not intended as an offer or solicitation with respect to the purchase or sale of any security or other financial instrument or any investment management services and should not be used as the basis for any investment decision. No risk management technique can guarantee the mitigation or elimination of risk in any market environment. Past performance is not a guarantee or a reliable indicator of future results and an investment could lose value. No liability whatsoever is accepted for any loss (whether direct, indirect, or consequential) that may arise from any use of the information contained in or derived from this report. PGIM and its affiliates may make investment decisions that are inconsistent with the recommendations or views expressed herein, including for proprietary accounts of PGIM or its affiliates. Any projections or forecasts presented herein are as of the date of this presentation and are subject to change without notice. Actual data will vary and may not be reflected here. Projections and forecasts are subject to high levels of uncertainty. Accordingly, any projections or forecasts should be viewed as merely representative of a broad range of possible outcomes. Projections or forecasts are estimated, based on assumptions, and are subject to significant revision and may change materially as economic and market conditions change. PGIM has no obligation to provide updates or changes to any projections or forecasts.

PGIM and its affiliates may develop and publish research that is independent of, and different than, the recommendations contained herein. PGIM’s personnel other than the author(s), such as sales, marketing and trading personnel, may provide oral or written market commentary or ideas to PGIM’s clients or prospects or proprietary investment ideas that differ from the views expressed herein.

  • Insights

    • Megatrends
    • Annual Best Ideas
    • OutFront Series
    • Quarterly Market Outlooks
    • Market Events
    • Thought Leadership
    • Events & Webinars
    • Video Library
    • Podcasts
  • Investment Themes

    • ESG Investing
    • Investing in Alternatives
    • Investing in Emerging Markets
    • Risk Management
  • Our Businesses

    • PGIM DC Solutions
    • PGIM Fixed Income
    • PGIM Investments
    • PGIM Multi-Asset Solutions
    • PGIM Private Alternatives
    • PGIM Private Capital
    • PGIM Real Estate
    • Montana Capital Partners (PE)
    • PGIM Quantitative Solutions
    • Jennison Associates
  • Clients

    • Clients We Serve
    • Defined Contribution
    • Financial Advisors
    • Institutional Relationships
  • About

    • Overview
    • Leadership
    • History
    • Diversity, Equity & Inclusion
    • Global Locations
    • Contact Us
    • Subscribe
    • Request for Information
  • Careers

    • Careers at PGIM
    • Job Opportunities
  • Newsroom

    • All News
    • Press Releases
    • In The News
    • Facts & Figures
    • Media Contacts
PGIM Logo
  • Terms & Conditions
  • Privacy Center
  • Accessibility Help
  • UK Regulatory Disclosures
  • Netherlands Regulatory Disclosures
  • Canadian Regulatory Disclosures
  • Ireland Gender Pay Gap Report
  • Cookie Preference Center

For Professional Investors only.* All investments involve risk, including the possible loss of capital.

This material is for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation in respect of any products or services to any persons who are prohibited from receiving such information under the laws applicable to their place of citizenship, domicile or residence. PGIM is the principal asset management business of Prudential Financial, Inc. and a trading name of PGIM, Inc. and its global subsidiaries. PGIM, Inc. is a registered investment adviser with the U.S. Securities and Exchange Commission (“SEC”). Registration with the SEC does not imply a certain level of skill or training.

The information on this website is not intended as investment advice and is not a recommendation about managing or investing your retirement savings. In making the information available on this website, PGIM, Inc. and its affiliates are not acting as your fiduciary.    

In the United Kingdom, this website may be issued by PGIM Private Alternatives (UK) Limited or PGIM Private Capital Limited.  In the European Economic Area (“EEA”), this website may be issued by PGIM Private Capital (Ireland) Limited or PGIM Luxembourg S.A. or PGIM Real Estate Germany AG.

PGIM, Inc. has its headquarters at 655 Broad Street, Newark, NJ 07102. PGIM Private Capital (Ireland) Limited has its registered office at IDA Business Park, Letterkenny, Co. Donegal, F92 FP83, Ireland. PGIM Private Capital (Ireland) Limited is authorised and regulated by the Central Bank of Ireland and registered in Ireland under company number 635793 operating on the basis of a European passport. PGIM Limited and PGIM Private Alternatives (UK) Limited have their registered offices at Grand Buildings, 1-3 Strand, Trafalgar Square, London WC2N 5HR. PGIM Limited is authorised and regulated by the Financial Conduct Authority (“FCA”) of the United Kingdom (Firm Reference Number: 193418). PGIM Private Alternatives (UK) Limited is authorised and regulated by the FCA of the United Kingdom (Firm Reference Number: 181389). PGIM Private Capital Limited has its registered address at 1 London Bridge, London SE1 9BG and is authorised and regulated by the FCA of the United Kingdom (Firm Reference Number: 172071). PGIM Luxembourg S.A., Netherlands Branch is registered with the Netherlands Chamber of Commerce under number 85998877 and has its local offices at Gustav Mahlerlaan 1212, 1088LA Amsterdam, The Netherlands. PGIM Luxembourg S.A. has its registered address at 2 Boulevard de la Foire, L-1528 Luxembourg and is authorised and regulated by the Commission de Surveillance du Secteur Financier (“CSSF”) in Luxembourg (registration number A00001218). PGIM Real Estate Germany AG has its registered address at Wittelsbacher Platz 1, 80333 Munchen, Germany and is authorised and regulated by Bundesanstalt für Finanzdienstleistungsaufsicht (“BaFin”) in Germany (registration number 10138142).

In Japan, information is provided by PGIM Japan Co., Ltd. (“PGIM Japan”) and/or PGIM Real Estate (Japan) Ltd. (“PGIMREJ”).  PGIM Japan, a registered Financial Instruments Business Operator with the Financial Services Agency of Japan offers various investment management services in Japan.  PGIMREJ is a Japanese real estate asset manager that is registered with the Kanto Local Finance Bureau of Japan.

In Hong Kong, information is provided by PGIM (Hong Kong) Limited, a regulated entity with the Securities & Futures Commission in Hong Kong to professional investors as defined in Section 1 of Part 1 of Schedule 1 of the Securities and Futures Ordinance (Cap. 571). In Singapore, information is issued by PGIM (Singapore) Pte. Ltd. (“PGIM Singapore”), a regulated entity with the Monetary Authority of Singapore under a Capital Markets Services License to conduct fund management and an exempt financial adviser. This material is issued by PGIM Singapore for the general information of “institutional investors” pursuant to Section 304 of the Securities and Futures Act 2001 of Singapore (the “SFA”) and “accredited investors” and other relevant persons in accordance with the conditions specified in Section 305 of the SFA. In South Korea, information is issued by PGIM, Inc., which is licensed to provide discretionary investment management services directly to South Korean qualified institutional investors on a cross-border basis.   

Prudential Financial, Inc. (“PFI”) of the United States is not affiliated in any manner with Prudential plc, incorporated in the United Kingdom or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom. 

*PGIM.com/Podcasts and its content is intended for informational or educational purposes only and is not directed exclusively to Professional Investors. 

PGIM Logo
PGIM Logo

You are viewing this page in preview mode.

Edit Page